Cann (ASX:CAN) share price shoots 16% higher on positive update

The Cann Group Limited (ASX: CAN) share price has jumped 16% today on news the company has shipped its first order to the United Kingdom.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cann Group Ltd (ASX: CAN) share price has rocketed up today on news the company has shipped its first order to a supply partner in the United Kingdom. At the time of writing, the Cann share price is up 13.3% at 56 cents after reaching an early high of 57.5 cents.

What did Cann announce?

In today's release, Cann advised that United Kingdom distribution partner, Astral Health has received its first shipment of medicinal cannabis oil.

Astral Heath, a member of the LYPHE Group, took delivery of the products as part of LYPHE's participation in Project Twenty21.

The exclusive supply agreement was formed with Astral Health in May 2020. The contract is valid for 5 years and will see Cann provide medicinal cannabis products to LYPHE through the Project Twenty21 initiative.

What is the LYPHE group?

The LYPHE Group is a leading European company that provides medicinal cannabis across an array of distribution channels. These include medicinal cannabis clinics, online pharmacies, and healthcare practitioner training.

More on Project Twenty21

Launched in November 2019, Project Twenty21 is a registry that enables access patients to acquire medical cannabis. In addition, the program records information on how effective the treatment is on each patient.

So far, more than 8,000 patients have enrolled into the registry through healthcare clinics or subscribing independently. This has made it the largest medicinal cannabis recruitment program undertaken in Europe. By the end of 2021, Project Twenty21 aims to enlist more than 20,000 patients, further improving access to treatment.

What did management say?

Cann Group CEO Shane Duncan said the company had worked hard to obtain all the necessary permit approvals.

With UK doctors able to prescribe Cann's medicinal cannabis products to patients from next week, he said:

It is an exciting step forward to get this first shipment off to support such a significant initiative in the UK, which helps position Cann as a leading supplier of medical cannabis in international markets that are continuing to gain momentum.

Cann share price summary

The Cann share price has been hit particularly hard during the wider COVID-19 market selloff this year. Its shares plunged from a 52-week high of $1.83 in January to an all-time low of 29 cents in October. That reflects an 84% decrease for shareholders over that period of time.

Although the Cann share price has surged higher today, it still has a long way to go to reach pre COVID-19 levels.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A group of people push and shove through the doors of a store, trying to beat the crowd.
Broker Notes

2 ASX shares highly recommended to buy: Experts

Are these two stocks the best buys on the ASX?

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Broker Notes

These ASX 200 shares could rise 20% to 55%

Brokers have good things to say about these shares.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Dividend Investing

I'd buy 5,883 shares of this ASX stock to aim for $1,000 of annual passive income

I’d pick this stock for its strong dividend record.

Read more »

A player pounces on the ball in the scoring zone of the field.
Best Shares

4 ASX 300 shares that ripped 100% or more in 2025

The S&P/ASX 300 Index rose 7.17% and delivered a total return, including dividends, of 10.66% in 2025.

Read more »

A little girl is about to launch down the slide with a blue sky and white clouds in the sky behind her.
Broker Notes

BHP vs. Fortescue shares: Goldman Sachs says 1 will rip and 1 will dip

Top broker Goldman Sachs upgraded its 12-month share price forecasts for BHP and Fortescue shares this week.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Brokers rate these 3 ASX shares as buys in January

These ASX shares have an exciting outlook according to experts.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why Australian Ethical, Northern Minerals, PLS, and Woodside shares are falling today

These shares are ending the week in the red. But why?

Read more »